Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21362815 | 0.71 | ALDH1A1 (0.34) | CACNA1HALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL878777 | 0.69 | POLB (0.46) | EPHX1ALDH1A1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL28206894 | 0.67 | KMT2A (0.34) | LMNAKMT2ASMN1; SMN2TSHR | |
| SCHEMBL6865274 | 0.67 | HMGCR (0.38) | ALDH1A1EPHX2LMNATSHR | |
| SCHEMBL16592071 | 0.66 | ALDH1A1 (0.39) | EPHX1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL14162078 | 0.66 | GRIN2D (0.34) | LMNASMN1; SMN2TSHR | |
| SCHEMBL16064880 | 0.66 | LMNA (0.51) | EPHX1ALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL14118984 | 0.66 | KMT2A (0.33) | EPHX1CACNA1HALDH1A1EPHX2LMNA | |
| SCHEMBL10108763 | 0.65 | ALDH1A1 (0.32) | ALDH1A1KMT2ATSHR | |
| SCHEMBL20684936 | 0.65 | ALDH1A1 (0.38) | ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566019-B2 | 2-pyrimidone analogs as potent antiviral agents against alphaviruses | SOUTHERN RESEARCH INSTITUTE (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220177452-A9 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-09 | — | — | US | disclosed |
| US-20210317106-A1 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | SOUTHERN RES INST (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317106-A1 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | EIF2AK2, ZC3HAV1, MAVS | EPHX1 580/4885CACNA1H 2498/4885ALDH1A1 492/4885 |
| US-11566019-B2 | 2-pyrimidone analogs as potent antiviral agents against alphaviruses | EIF2AK2, ZC3HAV1, MAVS | EPHX1 580/4885CACNA1H 2498/4885ALDH1A1 492/4885 |
| US-20220177452-A9 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | EIF2AK2, ZC3HAV1, MAVS | EPHX1 580/4885CACNA1H 2498/4885ALDH1A1 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.